Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer

British Journal of Cancer

Volumn 92, Issue 9, 2005, Pages 1626-1635

  Willits, I ^a   Price, L ^a   Parry, A ^a   Tilby, M J ^a   Ford, D ^b   Cholerton, S ^c   Pearson, A D J ^a,d   Boddy, A V ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

^d ROYAL VICTORIA INFIRMARY   (United Kingdom)

Author keywords

Comet; DNA damage; Ifosfamide; Paediatric

Indexed keywords

ACICLOVIR; ALIMEMAZINE; AMITRIPTYLINE; CARBAMAZEPINE; CEFALEXIN; CHLORAL HYDRATE; CHLORPROMAZINE; CLARITHROMYCIN; CODEINE PHOSPHATE; COTRIMOXAZOLE; CYCLAZOCINE; DACTINOMYCIN; DEXAMETHASONE; DIHYDROCODEINE; DNA; DOXORUBICIN; ETOPOSIDE; FUROSEMIDE; GAVISCON; IFOSFAMIDE; LORAZEPAM; METHYLENE BLUE; METOCLOPRAMIDE; NABILONE; ONDANSETRON; PARACETAMOL; RANITIDINE; TEICOPLANIN; TEMAZEPAM; VINCRISTINE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; COMET ASSAY; CONTINUOUS INFUSION; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA DAMAGE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; EWING SARCOMA; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS; RHABDOMYOSARCOMA;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHILD; CHILD, PRESCHOOL; COMET ASSAY; DNA DAMAGE; FEMALE; HUMANS; IFOSFAMIDE; MALE; NEOPLASMS;

EID: 19944416536     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602554     Document Type: Article

References (29)

1. Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A, Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E (1992) Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J Clin Oncol 10: 995-1000
2. Boddy AV, Cole M, Pearson ADJ, Idle JR (1995a) The kinetics of the autoinduction of ifosfamide metabolism during continuous-infusion. Cancer Chemother Pharmacol 36: 53-60
3. Boddy AV, English M, Pearson ADJ, Idle JR, Skinner R (1996) Ifosfamide nephrotoxicity: limited influence of metabolism and mode of administration during repeated therapy in paediatrics. Eur J Cancer 32A: 1179-1184
4. Boddy AV, Idle JR (1992) Combined thin-layer chromatography photography densitometry for the quantification of ifosfamide and its principal metabolites in urine, cerebrospinal-fluid and plasma. J Chromatogr Biomed Appl 575: 137-142
5. Boddy AV, Yule SM (2000) Metabolism and pharmacokinetics of oxazaphosphorines. Clin Pharmacokinet 38: 291-304
6. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1993) Pharmacokinetics and metabolism of ifosfamide administered as a continuous-infusion in children. Cancer Res 53: 3758-3764
7. Boddy AV, Yule SM, Wyllie R, Price L, Pearson ADJ, Idle JR (1995b) Comparison of continuous-infusion and bolus administration of ifosfamide in children. Eur J Cancer 31 A: 785-790
8. Boos J, Silies H, Hohenlochter B, Jurgens H, Blaschke G (1995) Short-term versus continuous infusion: no influence on ifosfamide side-chain metabolism. Eur J Cancer 31A: 2417-2418
9. Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM (2003) Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the intergroup rhabdomyosarcoma study IV. J Clin Oncol 21: 78-84
10. Carli M, Passone E, Perilongo G, Bisogno G (2003) Ifosfamide in pediatric solid tumors. Oncology 65: 99-104
11. Dockham PA, Lee MO, Sladek NE (1992) Identification of human liver aldehyde dehydrogenases that catalyze the oxidation of aldophosphamide and retinaldehyde. Biochem Pharmacol 43: 2453-2469
12. Fairbairn DW, Olive PL, Oneill KL (1995) The comet assay - a comprehensive review. Mutat Res Rev Genet Toxicol 339: 37-59
13. Hartley JM, Spanswick VJ, Gander M, Giacomini G, Whelan J, Souhami RL, Hartley JA (1999) Measurement of DNA cross-linking in patients on ifosfamide therapy using the single cell gel electrophoresis (COMET) assay. Clin Cancer Res 5: 507-512
14. Hininger I, Chollat-Namy A, Sauvaigo S, Osman M, Faure H, Cadet J, Favier A, Roussel AM (2004) Assessment of DNA damage by comet assay on frozen total blood: method and evaluation in smokers and non-smokers. Mutat Res Genet Toxicol Environ Mutagen 558: 75-80
15. Johnstone EC, Lind MJ, Griffin MJ, Boddy AV (2000) Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. Cancer Chemother Pharmacol 46: 433-441
16. Kamen BA, Frenkel E, Colvin OM (1995) Ifosfamide - should the honeymoon be over. J Clin Oncol 13: 307-309
17. Kerbusch T, de Kraker J, Keizer HJ, van Putten JWG, Groen HJM, Jansen RLH, Schellens JHM, Beijnen JH (2001a) Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites. Clin Pharmacokinet 40: 41-62
18. Kerbusch T, de Kraker J, Mathot RAA, Beijnen JH (2001b) Population pharmacokinetics of ifosfamide and its dechloroethylated and hydroxylated metabolites in children with malignant disease - a sparse sampling approach. Clin Pharmacokinet 40: 615-625
19. Kerbusch T, Mathot RAA, Keizer HJ, Kaijser GP, Schellens JHM, Beijnen JH (2001c) Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites. Drug Metab Dispos 29: 967-975
20. Kerbusch T, Mathot RAA, Keizer HJ, Ouwerkerk J, Rodenhuis S, Schellens JHM, Beijnen JH (2001d) Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma. Eur J Clin Pharmacol 57: 467-477
21. Misiura K, Zubowska M, Zielinska E (2003) Analysis of the urinary excretion of ifosfamide and its N-dechloroethylated metabolites in children using P-31-NMR spectroscopy. Arzneimittel-Forschung 53: 372-377
22. Moore MJ (1991) Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 20: 194-208
23. Rojas E, Lopez MC, Valverde M (1999) Single cell gel electrophoresis assay: methodology and applications. J Chromatogr B 722: 225-254
24. Silies H, Blaschke G, Hohenlochter B, Rossi R, Jurgens H, Boos J (1998) Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion. Int J Clin Pharmacol Therap 36: 246-252
25. Sladek N (1988) Metabolism of oxazaphosphorines. Pharmacol Therap 37: 301-355
26. Vela-Ojeda J, Tripp-Villanueva F, Montiel-Cervantes L, Sanchez-Cortes E, Ayala-Sanchez M, Guevara-Moreno ME, Garcia-Leon LD, Rosas-Cabral A, Esparza M, Gonzalez-Llaven J (2000) Prospective randomized clinical trial comparing high-dose ifosfamide plus GM-CSF vs high-dose cyclophosphamide plus GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplant 25: 1141-1146
27. Wainer IW, Ducharme J, Granvil CP, Trudeau M, Leyland-Jones B (1994) Ifosfamide stereoselective dechloroethylation and neurotoxicity. Lancet 343: 982-983
28. Walker D, Flinois JP, Monkman SC, Beloc C, Boddy AV, Cholerton S, Daly AK, Lind MJ, Pearson ADJ, Beaune PH, Idle JR (1994) Identification of the major human hepatic cytochrome-P450 involved in activation and N-dechloroethylation of ifosfamide. Biochem Pharmacol 47: 1157-1163
29. Yule SM, Price L, McMahon AD, Pearson ADJ, Boddy AV (2004) Cyclophosphamide metabolism in children with non-Hodgkin's lymphoma. Clin Cancer Res 10: 455-460